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Abstract
Background: Interleukin-1beta (IL-1β) is a pro-inflammatory cytokine that can be produced in the central nervous
system during inflammatory conditions. We have previously shown that IL-1β expression is altered in the rat brain
during a morphine tolerant state, indicating that this cytokine may serve as a convergent point between the
immune challenge and opiate mediated biological pathways. We hypothesized that IL-1β up-regulates opioid
receptors in human astrocytes in both untreated and morphine-desensitized states.
Methods: To test this hypothesis, we compared the basal expression of the mu (MOR), delta (DOR), and kappa
(KOR) opioid receptors in the human U87 MG astrocytic cell line to SH-SY5Y neuronal and HL-60 immune cells
using absolute quantitative real time RT-PCR (AQ-rt-RT-PCR). To demonstrate that IL-1β induced up-regulation of
the MOR, DOR and KOR, U87 MG cells (2 x 105 cells/well) were treated with IL-1β (20 ng/mL or 40 ng/mL), followed
by co-treatment with interleukin-1 receptor antagonist protein (IL-1RAP) (400 ng/mL or 400 ng/mL). The above
experiment was repeated in the cells desensitized with morphine, where U87 MG cells were pre-treated with
100 nM morphine. The functionality of the MOR in U87 MG cells was then demonstrated using morphine inhibition
of forksolin-induced intracellular cAMP, as determined by radioimmunoassay.
Results: U87 MG cells treated with IL-1β for 12 h showed a significant up-regulation of MOR and KOR. DOR
expression was also elevated, although not significantly. Treatment with IL-1β also showed a significant
up-regulation of the MOR in U87 MG cells desensitized with morphine. Co-treatment with IL-1β and interleukin-1
receptor antagonist protein (IL-1RAP) resulted in a significant decrease in IL-1β-mediated MOR up-regulation.
Conclusion: Our results indicate that the pro-inflammatory cytokine, IL-1β, affects opiate-dependent pathways by
up-regulating the expression of the MOR in both untreated and morphine-desensitized U87 MG.
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Background
In the brain, astrocytes are an important component of
the blood–brain barrier and participate in the mainten-
ance of homeostasis. They are also a main producer of
cytokines and chemokines [1]. In addition, astrocytes are
capable of surviving under inflammatory conditions and
are resistant to death receptor-mediated apoptosis [2].
Interleukin-1 (IL-1) is a pro-inflammatory cytokine
expressed in the central nervous system (CNS). It is pro-
duced by a wide variety of cells, such as glia, astrocytes,
neurons, monocytes and endothelial cells [3,4]. During
inflammation, IL-1 can activate the paraventricular nu-
cleus of the hypothalamus, resulting in the release of
corticotrophin-releasing hormone and subsequent activa-
tion of the hypothalamic-pituitary-adrenal (HPA) axis [4].
Three opioid receptors have been identified to date –
mu (MOR), delta (DOR) and kappa (KOR). Morphine,
which has a higher affinity for the MOR compared to
the KOR and DOR [5-7], elicits its effects mainly
through the MOR. Morphine is well known for its anal-
gesic effects and addictive properties [8], as well as its
ability to alter the endocrine and immune systems
[9,10]. Chronic morphine use can cause immunosup-
pression, and morphine addicts often have an increased
incidence of viral hepatitis, bacterial pneumonias, endo-
carditis, tuberculosis and CNS infections [11,12]. Con-
versely, chronic morphine exposure can also indirectly
potentiate an immune response by desensitizing the HPA
axis [9,13,14], and increasing the production and activity
of various cytokines, including IL-1β [15], IL-6 [16], and
TNF-α [14]. Early studies showed that IL-1 increases the
expression of opioid receptors in primary human glial
cells [17] and human brain microvascular primary cells
[3], suggesting that this pro-inflammatory cytokine may
possess neuromodulatory effects and may be an import-
ant component in the immune-opioid circuit.
In this study, we hypothesized that a functional relation-
ship may exist between IL-1β and the opioid receptors in
human astrocytes. We examined the ability of IL-1β to in-
crease expression of the MOR, DOR and KOR in a human
astrocytic cell line, U87 MG, both in the untreated state as
well as in the state desensitized with morphine. We then
examined whether IL-1β-induced MOR up-regulation is
mediated through the IL-1β receptor.
Methods
Materials
Cell culture and TRIzolW reagents were obtained from
GIBCO/Invitrogen (Carlsbad, CA, USA). Morphine, na-
loxone and 12-o-tetradecanoyl-phorbol-13-acetate (TPA)
and all other reagents used for RNA extraction were
obtained from Sigma (St. Louis, MO, USA). DAPI was
obtained from Pierce (Rockford, IL, USA), and antibodies
to the MOR were obtained from Chemicon (Rosemont,
IL, USA). Interleukin-1 beta (IL-1β) and interleukin-1 re-
ceptor antagonist protein (IL-1RAP) were obtained from
R& D Systems (Minneapolis, MN, USA).
U87 MG cells
Human astrocytoma cells (U87 MG), which have been
previously used to represent astrocytes in in vitro studies
[18-21], were obtained from American Type Culture
Collection (ATCC) (Rockville, MD, USA) and grown in
DMEM containing 10% FBS and 1% penicillin/strepto-
mycin sulfate in a humidified 5% CO2 at 37°C.
HL-60 cells
Human promyelocytic leukemia (HL-60) cells were
obtained from ATCC (Rockville, MD, USA) and cultured
in RPMI-1640 medium supplemented with 20% FBS and
1% penicillin/streptomycin sulfate. Cells were main-
tained at 37°C in humidified 5% CO2. The HL-60 cells
were induced to differentiate into macrophage/mono-
cyte-like cells with TPA (16 nM TPA/0.1% EtOH in
RPMI-1640 medium) for 4 d. The TPA-treated medium
was changed every 48 h until the completion of
differentiation.
NMB cells
Human neuroblastoma cells (NMB cells) were a gift
from Dr. Horace H. Loh (University of Minnesota,
MN, USA). NMB cells were grown and maintained in
RPMI-1640 medium containing 10% FBS. NMB cells
were maintained in a humidified environment of 5%
CO2 at 37°C.
SH-SY5Y cells
Human neuroblastoma cells (SH-SY5Y cells) were a gift
from Dr. Robert Ross (Fordham University, New York,
NY, USA). SH-SY5Y cells were grown and maintained
in a 1:1 mixture of Earle's Minimum Essential Medi-
um, Ham's Nutrient Mixture F12 and 10% FBS with
penicillin/streptomycin sulfate.
IL-1β treatment
U87 MG cells (2 x 105 cells/well) were treated with cell
culture medium containing either vehicle (cell culture
medium) or IL-1β (20 ng/mL or 40 ng/mL) for 0, 3, 6,
12, 24, or 48 h. The medium was aspirated and 1 mL
TRIzolW was added to each well. The cells were then
frozen and stored at −80°C for further analysis.
Co-treatment with IL-1β and IL-1RAP
U87 MG cells (2 x 105 cells/well) were treated with cell
culture medium containing either vehicle (cell culture
medium), IL-1β (20 ng/mL), IL-1RAP (400 ng/mL) +
vehicle, IL-1RAP (400 ng/mL) + IL-1β (20 ng/mL),
IL-1RAP (4,000 ng/mL) + vehicle, or IL-1RAP (4,000 ng/mL)
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+ IL-1β (20 ng/mL). IL-1RAP concentrations (400 ng/mL
and 4,000 ng/mL) exceeded the manufacturer’s recom-
mendation of a 1:100 ratio of IL-1β to IL-1RAP needed
for IL-1RAP to be effective. Cells were then incubated in
5% CO2 at 37°C for 12 h. The medium was aspirated and
1 mLTRIzolW was added to each well. The cells were then
frozen and stored at −80°C for further analysis.
Time course of morphine’s effects on the MOR
U87 MG cells (1.5 x 105 cells/well) were treated with fresh
cell culture medium containing either vehicle or 100 nM
morphine. Cells were incubated in 5% CO2 at 37°C for
45 minutes, 3, 6, 12, 24, or 48 hours. The medium was aspi-
rated and 1 mL TRIzolW was added to each well. The cells
were then frozen and stored at −80°C for further analysis.
Pre-treatment U87 MG cells with morphine,
followed by IL-1β
U87 MG cells (1.5 x 105 cells/well) were treated with cell
culture medium containing vehicle (cell culture medium)
or 100 nM morphine [22]. Cells were incubated in 5%
CO2 at 37°C for 24 h. The medium was aspirated and the
cells were treated with fresh medium containing either ve-
hicle or IL-1β (20 ng/mL). Cells were incubated in 5%
CO2 at 37°C for 12 h. The medium was aspirated and
1 mLTRIzolW was added to each well. The cells were then
frozen and stored at −80°C for further analysis.
RNA isolation
Total RNA was extracted using TRIZOLW reagent
according to the manufacturer’s instructions (Invitrogen,
Grand Island, NY, USA). Each treatment was performed
in triplicate. The RNA was dissolved in RNase-free DEPC
water, and the concentration of each sample was
determined at an optical density of 260 nm, 280 nm
and 320 nm using an ND-1000 Spectrophotometer
(NanoDrop Technologies, Inc., Wilmington, DE, USA).
Forskolin-induced cAMP accumulation assay
To evaluate the functionality of the MOR expressed in the
U87 MG cells, a forskolin-induced cAMP accumulation
assay as described previously [23], was conducted in U87
MG cells with and without morphine treatment. Each
sample was assayed in triplicate. Upon reaching appropri-
ate confluency (approximately 60 to 80%), the medium
was removed and replaced with medium containing
0.5 mM IBMX, a phosphodiesterase inhibitor that blocks
the breakdown of cAMP. The cells were incubated in 5%
CO2 at 37°C for 30 minutes. The medium was aspirated
and the cells were treated with 0.5 mL fresh medium con-
taining either vehicle, 75 μM forskolin, 10 μM morphine,
10 μM morphine + 75 μM forskolin, or 10 μM morphine +
75 μM forskolin + 10 μM naloxone (a MOR antagonist).
The cells were returned to the incubator for 10 minutes at
37°C. The medium was removed and the cells were washed
twice with 1X PBS, then lysed with 0.1 N HCl. The cell
lysates were frozen at −20°C until intracellular cAMP levels
were measured using a commercially available RIA
kit (Amersham Biosciences, Inc., Piscataway, NJ, USA). Par-
allel studies were conducted using two opioid peptides with
a high affinity for the MOR, endomorphin-1 (10 μM) or
endomorphin-2 (10 μM), in place of morphine.
Radioimmunoassay (RIA)
Intracellular cAMP levels were measured in the thawed cell
lysates by radioimmunoassay using the manufacturer’s
protocol (Amersham Biosciences, Inc.). Each sample was
assayed in triplicate. The cell lysate (10 μl), antiserum
(100 μl) and I125 cAMP (100 μl) were added to glass culture
tubes, vigorously shaken for two minutes, and then incu-
bated overnight at RT. Following the incubation, 250 μl of
Amelex-M secondary antibody was added to each tube, and
the samples were incubated at RT for 10 minutes. Samples
were then centrifuged for 15 minutes at 1,500 rpm at RT.
The supernatant was decanted from each glass tube into a
radioactive labeled container. A Wallac Wizard Gamma
Counter 1470 was used to determine the amount of radio-
activity (PerkinElmer, Waltham, MA, USA).
Immunofluorescent staining
U87 MG cells were plated in a slide chamber containing
500 μl of DMEM + 10% FBS per chamber until 60 to
80% confluent. The U87 MG cells were then fixed in a
paraformaldehyde and formaldehyde solution. The cells
were washed with 1X PBS with Ca/Mg and dried. Slides
were then incubated with a primary antibody [rabbit
anti-MOR (1:1,000)] overnight at 4°C. Slides were
washed with PBS and incubated with goat anti-rabbit
IgG- FITC (1:1,000) for 2 h at RT. The nuclei
were stained with DAPI for 20 minutes at RT, then
washed with PBS. Confocal microscopy was used to
visualize the sample (Olympus FluoViewTM 1000, Center
Valley, PA, USA).
Real time reverse transcription polymerase chain
reaction (rt-RT-PCR)
Absolute quantitative (AQ-rt-RT-PCR) and relative
(rt-RT-PCR) real time PCR was performed to determine
MOR, KOR, DOR and GAPDH expression levels follow-
ing methods described in our published study [24].
Briefly, one microgram of total RNA was reverse tran-
scribed to synthesize the first-strand cDNA on a Gen-
eAmp 2400 Thermocycler (PerkinElmer) using 200 units
of M-MLV reverse transcriptase, 10 mM DTT, 0.5 mM
dNTP, 1X RT buffer, 5 ng/mL random primer and DEPC
H2O for a total reaction volume of 20 μl (Invitrogen).
Thermal cycling conditions were 37°C for 60 minutes,
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followed by a 10-minute incubation period at 65°C. The
reaction was then cooled on ice. The cDNA (2 μl) was
then amplified using real time PCR in a 50 μl PCR mas-
ter mix (1 μl cDNA, 25 μl of 2X TaqManW universal
master mix, 1 μl of each probe (200 nM), 1 μl of each
primer (400 nM), and 22 μl of DEPC H2O) in an ABI
Prism 7000W (Applied Biosystems, Foster City, CA,
USA). The PCR primers for MOR amplification were: 5'-
TACCGTGTGCTATGGACTGAT-3' (sense), 5’-ATGAT-
GACGTAA ATG- TGAATG-3' (antisense) and 5'/56
FAM/ CTTGCGCCTCAAGAGTGTCCGCA/ 3BHQ_1/-
3' (probe). The primer for KOR amplification were: 5'-
CGTCTGCTAC- ACCCTGATGATC-3' (sense), 5'-CTC
TCGGGAGCCAGAAAGG-3' (antisense), and 5/56-HEX/
TGCGTCTCAAGAGCGTCCGGC/3BHQ_2/-3’ (probe).
The primers for DOR amplification were: 5'-GCGG
GAAAGCCAGTGACTC-3' (sense), 5'-TGCCCTGTTTA
AGGACTCAGTTG-3' (antisense), and 5'/56-JOE/AGG
AGAG- GAGCGGGACCTGTGGCT/3BHQ_1/-3' (probe).
A GAPDH mRNA fragment was also amplified for
normalization of the MOR mRNA levels as previously
described (Lai et al., 2003) with the following sequence of
primers and TaqMan probe: 5'-GGAAGCTCACTGG
CATGGC-3' (sense), 5'-TAGACGGCAGGTCA- GGTCCA-
3' (antisense) and 5'/56-FAM/CCCCACTGCCAACGTG
TCAGTG/ 3BHQ_1/-3' (probe). The conditions for ther-
mal cycling were as follows: 95°C for 10 minutes, followed
by 40 cycles at 95°C for 18 s, then at 60°C for 1 minute.
Analysis of the results was performed using the ABI
Prism 7000W Sequence Detection System from Applied
Biosystems.
PCR data analysis
PCR data were analyzed based either on copy number or
comparative CT values (ΔΔCT). Copy number was deter-
mined using the standard curve method to determine
copy number of the selected mRNA [24]. Briefly, the
ABI PRISM 7000 Sequence Detection System software
was utilized to determine the standard curve of the
amplification of the appropriate sample using the ap-
propriate standards (MOR, KOR, DOR and so on).
The mean copy number was then determined for each
treatment group, and the copy number of each sample
was then normalized against a housekeeping control
(GAPDH).
The comparative CT method is a method used to de-
termine threshold cycles (CT), the number of cycles that
the fluorescence generated crosses a threshold as
described previously [25]. Briefly, the CT values were
generated from the ABI PRISM 7000 Sequence Detec-
tion System software, and mean CT values were deter-
mined for each treatment group. The difference in CT
values (ΔCT) was then determined by subtracting the
mean CT of the test samples from the mean CT of the
reference RNA. The ΔCT for the test sample was then
subtracted from the ΔCT for the control sample to gen-
erate a ΔΔCT as follows: ΔΔCT = ΔCT (test sample)
−ΔCT (control). The ΔΔCT measurements were used to
calculate expression of the test sample relative to the
control and normalized to the untreated control: relative
expression (fold change) = 2−ΔΔCT .
Statistical analysis
Data are presented as the mean ± SE. Statistical data
were analyzed using either a one-way ANOVA, paired or
unpaired Student’s t-test, as appropriate. Statistical sig-
nificance was considered at P <0.05.
Results
Basal opioid receptor expression in immune and neuronal
cell lines
Opioid receptor expression in the U87 MG astrocytoma
cell line was compared to TPA-differentiated and undif-
ferentiated HL-60 immune cells and SH-SY5Y and NMB
neuronal cells. All of the cell lines examined expressed
all three opioid receptors - MOR, DOR and KOR - al-
though the levels of expression of each receptor varied
in different cell lines. SH-SY5Y cells had the highest
MOR expression (1.63 x 107 ± 0.41 x 107 copies of
MOR/μg of total RNA) compared to the TPA-
differentiated HL-60 cells (6.06 x 105 ± 0.30 x 105 copies
of MOR/μg of total RNA), undifferentiated HL-60 cells
(1.43 x 105 ± 0.67 x 105 copies of MOR/μg of total
RNA), NMB cells (9.5 x 104 ± 4.8 x 104 copies of MOR/
μg of total RNA), and U87 MG cells (3.43 x 105 ± 0.67 x
105 copies of MOR/μg of total RNA). NMB cells
expressed the highest levels of DOR (3.68 x 107 ± 0.48 x
107 copies of DOR/μg of total RNA) compared to the
TPA-differentiated HL-60 cells (1.94 x 106 ± 0.3 x 106
copies of DOR/μg of total RNA), undifferentiated HL-60
cells (1.26 x 106 ± 0.06 x 106 copies of DOR/μg of total
RNA), SH-SY5Y cells (1.67 x 107 ± 0.41 x 107 copies of
DOR/μg of total RNA), and U87 MG cells (7.86 x 105 ±
0.06 x 105 copies of DOR/μg of total RNA). TPA-
differentiated HL-60 cells had the highest KOR expression
(2.18 x 107 ± 0.30 x 107 copies of KOR/μg of total RNA)
compared to HL-60 cells (5.55 x 106 ± 0.14 x 106 copies of
DOR/μg of total RNA), NMB cells (1.17 x 107 ± 0.48 x 107
copies of DOR/μg of total RNA), SH-SY5Y cells (2.25 x
104 ± 0.32 x 104 copies of DOR/μg of total RNA), and U87
MG cells (1.21 x 105 ± 0.13 x 105 copies of DOR/μg of
total RNA) (Figure 1).
Immunofluorescence staining of the MOR in U87 MG cells
Immunofluorescence staining was used to further
characterize the basal expression of the MOR in the U87
MG cells. U87 MG cells stained with goat anti-rabbit
IgG alone served as a negative control (Figure 2A). DAPI
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staining was used to stain the nucleus, as shown in blue
(Figure 2B). Rabbit anti-MOR staining indicated basal
levels of MOR expression in the U87 MG cells, as indi-
cated in green (Figure 2C, E). A superimposed image
(Figure 2D) indicates the position of the MOR relative
to the nucleus.
Functionality of the MOR expressed in the U87 MG cells
The MOR is a G protein-coupled receptor that, upon ac-
tivation, initiates a signaling cascade that inhibits adeny-
lyl cyclase, which in turn decreases intracellular cAMP
levels [26]. In order to determine the functionality
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Figure 1 Basal levels of MOR, DOR and KOR mRNA in neuronal and immune cell lines. Basal levels (copy number) of the human MOR, DOR
and KOR in the U87 MG astrocytic, HL-60 (TPA differentiated and undifferentiated), NMB, and SH-SY5Y cell lines were determined using absolute
quantitative real time RT-PCR (AQ-rt-RT-PCR). GAPDH was used to normalize the levels in each cell line. Data are indicated as the mean ± SE.
A: IgG B: DAPI stain 
D: MOR and DAPI C: MOR stain 
E: MOR 
Figure 2 Immunofluorescence staining of the human MOR. Immunofluorescence staining was used to visualize the basal expression level
of the human MOR. (A) U87 MG cells stained with goat anti-rabbit IgG (1:1,000) alone (negative control); (B) U87 MG cells stained with
4'-6-diamidino-2-phenylindole (DAPI) (1:1,000); (C and E) U87 MG cells stained with rabbit anti-MOR (1:1,000); (D) A superimposed image of B
and C to show location of the MOR.
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induced cAMP assay was conducted. As expected,
forskolin (75 μM), an adenylyl cyclase activator, signifi-
cantly increased cAMP levels (6.0 ± 0.25 pmol/μg
protein) as compared to untreated control cells (0.1 ±
0.005 pmol/μg protein). U87 MG cells treated with
morphine (10 μM) showed similar cAMP levels (0.3 ±
0.05 pmol/μg protein) as the control (0.1 ± 0.005 pmol/μg
protein). U87 MG cells treated with morphine (10 μM)
plus forskolin (75 μM) exhibited a significant decrease
in cAMP levels (1.4 ± 0.075 pmol/μg protein) as com-
pared to forskolin alone treated cells (6.0 ± 0.25 pmol/
μg protein). The addition of a MOR antagonist, nalox-
one (10 μM), also increased cAMP levels (4.5 ±
0.075 pmol/μg protein) similar to forskolin (Figure 3A).
Endomorphin-1 and endomorphin-2 are potent
endogenous MOR agonists [27]. Treatment with
endomorphin-1 or endomorphin-2 increased cAMP
production similar to that observed with morphine
treatment (Figure 3B).
IL-1β-induced up-regulation of the MOR, DOR and KOR in
U87 MG cells
A significant increase in MOR expression was seen in a
dose dependent manner in the U87 MG cells treated
with IL-1β at 20 ng/mL and 40 ng/mL for 12 h (5.35 ±
0.44 and 14.5 ± 0.32, respectively) compared to control
(Figure 4A). U87 MG cells treated with 40 ng/mL,
but not 20 ng/mL, IL-1β had a significant increase in
DOR compared to control (1.74 ± 0.24) (Figure 4B). A
significant increase in KOR was observed in a dose
dependent manner with 20 ng/mL and 40 ng/mL IL-1β
(1.79 ± 0.27 and 2.09 ± 0.27, respectively) compared to
the control (Figure 4C).
Figure 3 The effects of morphine, naloxone,and endomorphin-1 and endomorphin-2, on forskolin-induced cAMP levels. Functionality of
the MOR expressed in U87 MG cells was determined using a forskolin-induced cAMP accumulation assay. (A) cAMP accumulation levels were
determined in basal (untreated) U87 MG cells and in U87 MG cells treated with forskolin alone (75 μM), morphine alone (10 μM), forskolin
(75 μM) +morphine (10 μM), or forskolin (75 μM) +morphine (10 μM) + naloxone (10 μM); (B) cAMP accumulation levels were determined in
basal (untreated) U87 MG cells and in U87 MG cells treated with forskolin alone (75 μM), endomorphin-1 alone (10 μM), endomorphin-2 alone
(10 μM), fosrkolin (75 μM) + endomorphin-1 (10 μM), forskolin (75 μM) + endomorphin-2 (10 μM), forskolin (75 μM) + endomorphin-1 (10 μM) +
naloxone (10 μM), or forskolin (75 μM ) + endomorphin-2 (10 μM) + naloxone (10 μM). Data are the mean ± SE. A one-way ANOVA was used to
determine significance. *P <0.05 compared to basal treatment; ^P <0.05 compared to forskolin treatment alone.
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IL-1β up-regulation of MOR expression via the
IL-1β receptor
IL-1β exerts its biological effects by binding to
interleukin-1 receptor 1 (IL-1R1). An antagonist to this
receptor, interleukin-1 receptor antagonist protein (IL-
1RAP), has been shown to decrease IL-1β’s effects
[28]. We used IL-1RAP to examine whether IL-1β’s up-
regulation of the MOR is mediated through the IL-1R1.
U87 MG cells treated with IL-1β (20 ng/mL) demon-
strated an increase in the MOR (3.8 ± 0.05) compared to
the U87 MG cells treated with control (Figure 5). U87
MG cells treated with IL-1RAP (400 ng/mL) + vehicle
showed a significant decrease in MOR expression
(0.16 ± 0.64) compared to IL-1β treatment alone or
control. Co-treatment with IL-1RAP (400 ng/mL) + IL-1β
(20 ng/mL) also resulted in a significant decrease of
the MOR (0.36 ± 0.27) compared to the vehicle treated
control and to IL-1β alone.
U87 MG cells treated with a higher concentration of
IL-1RAP (4,000 ng/mL) + vehicle showed no difference
Figure 4 The effects of IL-1β on opioid expression in U87 MG cells. U87 MG cells were treated with either cell culture medium (control) or
IL-1β (20 ng/mL or 40 ng/mL) for 12 h. Real time RT-PCR was used to determine the levels of MOR (A), DOR (B), and KOR (C); GAPDH was
used to normalize the receptor levels. Data are the mean ± SE. A Student’s t-test was used to determine significance. *P <0.05 compared to
control cells.
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in MOR expression (0.89 ± 0.24) compared to vehicle
alone; however, there was a significant decrease com-
pared to IL-1β alone (3.8 ± 0.05). The co-treatment with
IL-1RAP (4,000 ng/mL) + IL-1β (20 ng/mL) resulted in a
significant decrease in the MOR (0.43 ± 0.38) compared
to the control and to IL-1β alone (Figure 5).
The effects of morphine pre-treatment on IL-1β
up-regulation of the MOR in U87 MG cells
Chronic exposure to morphine desensitizes the MOR
[29]. To further examine the immune-opioid relation-
ship, IL-1β’s ability to potentially up-regulate a desensi-
tized MOR after chronic morphine treatment was
examined. A desensitization time course indicated that
U87 MG cells treated with 100 nM morphine for 45 min-
utes had a significant decrease in the copy number of
the MOR (2.5 x 104 ± 3.7 x 103 copies of MOR/μg total
RNA) compared to the control (9.4 x 103 ± 3.2 x 103
copies of MOR/μg total RNA). Interestingly, after 3 h of
morphine treatment, the MOR was significantly
increased (1.9 x 106 ± 2.9 x 104 copies of MOR/μg total
RNA) compared to the control. However, MOR expres-
sion again decreased after 6 h (7.0 x 105 ± 2.9 x 104 cop-
ies of MOR/μg total RNA), 12 h (4.4 x 105 ± 1.4 x 104
copies of MOR/μg total RNA), 24 h (2.2 x 105 ± 2.3 x
104 copies of MOR/μg total RNA), and 48 h (2.9 x 105 ±
9.3 x 104 copies of MOR/μg total RNA) of morphine
treatment compared to control (Figure 6).
In order to examine IL-1β’s ability to restore MOR
levels after desensitization, U87 MG cells were treated
with morphine (100 nM) for 24 h, followed by treatment
with either vehicle or IL-1β (20 ng/mL) for 12 h. Cells
treated with IL-1β alone exhibited similar MOR expres-
sion (0.9 ± 0.15) as the vehicle treated control (1.0 ± 0.8)
(Figure 7). Cells treated with 100 nM morphine + vehicle
showed a significant increase in MOR levels (2.94 ± 0.35)
compared to the control. Cells treated with 100 nM
morphine, followed by 20 ng/mL IL-1β for 12 h signifi-
cantly increased MOR expression (7.32 ± 0.24) compared
to the control as well as compared to cells treated with
100 nM morphine + vehicle.
Discussion
In this study, we examined (a) the change in MOR ex-
pression in U87 MG human astrocytes exposed to IL-1β;
(b) the ability of IL-1β to up-regulate the MOR desensi-
tized by chronic morphine exposure; and (c) the role of
the IL-1 receptor in IL-1β-mediated up-regulation of the
MOR. Prior work in our laboratory showed that there is
an alteration in LPS-induced cytokine expression when
an animal is in a morphine tolerant state [14,30,31].
U87 MG cells are known to possess IL-1R1, the func-
tional receptor for the IL-1 pro-inflammatory cytokine
family [32]; however, the opioid receptors in this cell line
have not yet been characterized. Using real time RT-
PCR, we first determined the basal levels of the opioid
receptors in the U87 MG cells. Our results showed that
U87 MG cells exhibit moderate basal expression of all
three receptors: MOR, DOR and KOR. We then verified
that MOR is functionally active in the U87MG cells.
MOR is a G-protein coupled receptor (GPCR) and inhi-
bits adenylyl cyclase, which in turn decreases intracellu-
lar cAMP levels [33]. As a positive control, forskolin,
which is known to activate adenylyl cyclase and increase
cAMP levels, was used [34]. We also used morphine and
other MOR agonists, such as endomorphin 1 and 2, as
well as a MOR antagonist, naloxone. Our results show
that the morphine and endomorphins were able to de-
crease the cAMP levels, whereas naloxone reverses the
inhibitory effect, as we had expected. This proved that
the MOR is functionally active in U87 MG cells and,
therefore, is a good cell model to study the MOR signal-
ing and activity.
Figure 5 The effects of IL-1RAP on IL-1β-induced up-regulation of the MOR in U87 MG cells. U87 MG cells were treated with medium
(control), IL-1β (20 ng/mL), IL-1RAP (400 ng/mL) + vehicle, IL-1RAP (400 ng/mL) + IL-1β (20 ng/mL), IL-1RAP (4,000 ng/mL) + vehicle, or IL-1RAP
(4,000 ng/mL) + IL-1β (20 ng/mL) for 12 h. Real time RT-PCR was used to determine the levels of the MOR; GAPDH was used to normalize the
MOR levels. Data are the mean ± SE. A Student t-test was used to determine significance. *P <0.05 compared to control; ^P <0.001 compared to
IL-1β (alone); #P <0.01 compared to IL-1β (alone).
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We then examined IL-1β’s ability to modulate the ex-
pression of the opioid receptors. IL-1β induced a signifi-
cant increase in MOR, DOR, and KOR, which is
consistent with prior reports that IL-1 can induce MOR
expression in human neural microvascular endothelial
cells [3]. Although all three types of opioid receptors
were significantly up-regulated by IL-1β, the increase in
MOR was much more pronounced than DOR or KOR,
suggesting that the MOR is a more potent mediator of
an immune-opioid relationship than the DOR or KOR.
Mohan et al. (2010) reported a similar observation in
SK-N-SH neuroblastoma cells where MOR expression
was increased after treatment with IL-1β. Since IL-1
cytokines are known to increase transcription through
several different pathways, such as mitogen-activated
protein kinases (MAPKs) and nuclear factor-κB (NF-κB),
this could, in part, explain the increase in the opioid re-
ceptor transcription that is observed after IL-1β treat-
ment [35,36].
The ability of morphine to desensitize opioid receptors
is well established, as is the ability of IL-1β to up-
regulate the MOR in neural microvascular endothelial
cells, neuronal cells and glial cells [3,17,29]. In this
study, we examined the ability of IL-1β to affect
Figure 7 The effects of morphine pre-treatment on IL-1β-induced up-regulation of the MOR in U87 MG cells. U87 MG cells were
pre-treated with either vehicle (control) or morphine (100 nM) for 24 h. Following pre-treatment, the medium was aspirated and fresh cell culture
medium containing either vehicle or IL-1β (20 ng/mL) was added and the cells were incubated for 12 h. Absolute quantitative real time RT-PCR
(AQ-rt-RT-PCR) was used to determine expression of the MOR and GAPDH. Levels of MOR were normalized to GAPDH. Data are the mean ± SE. A
Student’s t-test was used to determine significance. *P <0.05 compared to the control; #P <0.05 compared to IL-1β (alone); ^P <0.001 compared
to the control.
Time
Figure 6 The effects of morphine on MOR expression in U87 MG cells. U87 MG cells were treated with either vehicle (cell culture medium)
or morphine (100 nM) for 0 (control), 45 minutes, 3, 6, 12, 24, or 48 hours. Real time RT-PCR was used to determine the copy number of the MOR
and GAPDH. GAPDH levels were used to normalize the MOR levels. Each time-point was adjusted by the appropriate time-point control. Data are
the mean ± SE. A Student’s t-test was used to determine significance. *P <0.05 compared to control.
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desensitized MOR in U87 MG cells. A time course
revealed that MOR expression increased significantly
after 3 h of morphine exposure, followed by a
desensitization of the MOR. After 24 h of pretreatment
with morphine, there was an increase in IL-1β-induced
MOR expression in U87 MG as compared to U87 MG
cells not pretreated with morphine. This was potentially
due to a rebound effect which occurred when the
morphine-containing medium was aspirated and
replaced with non-morphine containing medium. The
removal of the morphine-enriched medium could have
precipitated cellular morphine withdrawal, which can
cause MOR up-regulation [6]. However, morphine-
desensitized U87 MG cells treated with IL-1β showed a
significant increase in the MOR as compared to mor-
phine treated cells not exposed to IL-1β. These data in-
dicate that pro-inflammatory cytokines are able to
modulate opioid receptors, both in an untreated and a
morphine desensitized state in astrocytes. Pro-
inflammatory cytokines, such as IL-1β, can affect the
opioid-dependent pathways by stimulating the expres-
sion of the opioid receptors. Conversely, opioids, such as
morphine, can induce the production of inflammatory
cytokines. In rodent models, IL-1β expression was
increased after administration of chronic morphine [37].
In another study, morphine was found to activate the
toll-like receptor 4 (TLR4) in addition to the MOR.
TLR4 is present on immune cells, such as microglia,
which, upon activation, release pro-inflammatory cyto-
kines, such as IL-1 [38]. Similar observations were
reported in endothelial and neuroblastoma cells where
morphine and IL-1β co-treatment increased MOR ex-
pression, which further substantiated our data [15,35].
IL-1RAP, an antagonist to the IL-1 receptor, was then
used to determine the role of the IL-1β receptor in the
modulation of the MOR. U87 MG cells treated with a
high ratio of IL-1β to IL-1RAP (1:20) showed a signifi-
cant decrease in MOR expression, whereas U87 MG
cells treated with a low ratio of IL-1βto IL-1RAP (1:200)
showed no difference in MOR expression compared to
the control (only vehicle); however, there was a signifi-
cant decrease in IL-1β-induced MOR expression com-
pared to cells treated with only IL-1β. This indicates
that the effect of IL-1β on MOR expression in U87 MG
cells occurs through IL-1R1. The inability of the higher
concentration of IL-1RAP to completely block IL-1β-
induced up-regulation of the MOR expression could
be because of over-saturation of the U87 MG cells. An-
other reason could be that high concentrations of IL-
1RAP (without co-treatment of IL-1β) can decrease
basal levels of IL-1β to such an extent that there is a
negative feedback mechanism. Shavit et al. reported that
acute administration of IL-1RAP in mice immediately
after termination of morphine-induced analgesia,
resulted in an induction of analgesia suggesting the
MOR was probably up-regulated and, hence, analgesia
was reinstated [39].
Since astrocytes co-exist with neuronal cells in the
nervous system, it is important to take into account the
effect of one on the other. It has been seen that lipopoly-
saccharide (LPS) stimulates MOR expression in both
neuronal and macrophage-like cell models, through ac-
cumulation of reactive oxygen species (ROS) and pro-
inflammatory cytokines [40], leading to further immune
suppression and, thus, bringing about homeostasis. This
suggests that IL-1β not only stimulates MOR expression
in astrocytes but also in neuronal and other immune
cells, highlighting the involvement of opioid receptors in
the neuroimmune axis.
Our data also simulate the conditions seen in Human
Immunodeficiency Virus 1 (HIV-1) infection, where IL-
1β expression is up-regulated through activation of the
NLAP3 inflammasome [41]. Since the derogatory effects
of opioids on HIV-1 infection have been widely reported,
it is possible that the HIV-1 induced increase in IL-1β
secretion can also increase MOR expression in astro-
cytes, as suggested by our data.
Conclusion
Our findings showed that IL-1β can increase the expres-
sion of the MOR, DOR and KOR in a human astrocytic
cell line, U87 MG, both in the untreated state as well as
in a state desensitized with morphine. This modulation
is mediated through the IL-1β receptor. This suggests
that, upon exposure to an inflammatory stimulus, activa-
tion of pro-inflammatory cytokines, such as IL-1β,
occurs, stimulating the expression of the MOR, which
could further suppress the inflammatory response and
restore homeostasis.
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